

Paolo Zocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8486496/publications.pdf>

Version: 2024-02-01

25
papers

659
citations

933447

10
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

979
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. <i>Journal of Personalized Medicine</i> , 2022, 12, 990.	2.5	2
2	Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. <i>International Journal of Cardiology</i> , 2021, 325, 37-44.	1.7	5
3	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E188-E196.	1.7	6
4	First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial. <i>Circulation Journal</i> , 2021, 85, 1983-1990.	1.6	11
5	Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial. <i>Coronary Artery Disease</i> , 2021, 32, 51-57.	0.7	2
6	Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 217.	6.8	11
7	Three-year clinical outcome in all-comers with silent diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E110-E118.	1.7	8
8	New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials. <i>American Heart Journal</i> , 2020, 228, 109-115.	2.7	3
9	Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents. <i>Current Opinion in Cardiology</i> , 2020, 35, 705-711.	1.8	4
10	Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1100-1109.	2.9	26
11	Proximal LAD Treated With Thin-Strut New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 808-816.	2.9	3
12	Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E508-E515.	1.7	12
13	Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1650-1660.	2.9	44
14	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels. <i>JAMA Cardiology</i> , 2019, 4, 659.	6.1	56
15	5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 462-469.	2.9	41
16	Silent Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 448-459.	2.9	22
17	Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	5
18	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. <i>American Heart Journal</i> , 2018, 198, 25-32.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Serial assessment of endothelial function 1, 6, and 12 months after ST-elevation myocardial infarction. <i>Heart and Vessels</i> , 2018, 33, 978-985.	1.2	1
20	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1235-1245.	13.7	112
21	High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. <i>International Journal of Cardiology</i> , 2018, 268, 11-17.	1.7	19
22	High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 567-576.	2.6	7
23	Late clinical outcome of stent trials: a matter of life or death?. <i>Lancet, The</i> , 2018, 392, 713-714.	13.7	1
24	Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. <i>EuroIntervention</i> , 2017, 13, 1168-1176.	3.2	42
25	Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. <i>Lancet, The</i> , 2016, 388, 2607-2617.	13.7	208